Immune checkpoint blockade: a common denominator approach to cancer therapy.

The immune system recognizes and is poised to eliminate cancer but is held in check by inhibitory receptors and ligands. These immune checkpoint pathways, which normally maintain self-tolerance and limit collateral tissue damage during anti-microbial immune responses, can be co-opted by cancer to evade immune destruction. Drugs interrupting immune checkpoints, such as anti-CTLA-4, anti-PD-1, anti-PD-L1, and others in early development, can unleash anti-tumor immunity and mediate durable cancer regressions. The complex biology of immune checkpoint pathways still contains many mysteries, and the full activity spectrum of checkpoint-blocking drugs, used alone or in combination, is currently the subject of intense study.

• Publication year

  2015

• Venue

  Cancer Cell

• Publication date

  2015-04-13

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ccell.2015.03.001PMID 25858804PMCID PMC4400238
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

  2015cited by this paper
• Antagonists of PD-1 and PD-L1 in Cancer Treatment.

  2015cited by this paper
• PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

  2015cited by this paper
• Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

  2015cited by this paper
• Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints

  2015cited by this paper
• Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors.

  2014cited by this paper
• Cancer Immunology at the Crossroads: Experimental Immunotherapies Killer Immunoglobulin-like Receptors and Tumor Immunity

  2014cited by this paper
• Balance and imbalance in the immune system: life on the edge.

  2014cited by this paper
• CEACAM1 regulates TIM-3-mediated tolerance and exhaustion

  2014cited by this paper
• Role of Lymphocyte Activation Gene-3 (Lag-3) in Conventional and Regulatory T Cell Function in Allogeneic Transplantation

  2014influential reference
• MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

  2014cited by this paper
• Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues.

  2014cited by this paper
• The Role of Abiotic Environmental Conditions and Herbivory in Shaping Bacterial Community Composition in Floral Nectar

  2014cited by this paper
• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

  2014cited by this paper
• VISTA is an immune checkpoint molecule for human T cells.

  2014cited by this paper
• Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

  2014cited by this paper
• Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

  2014cited by this paper
• The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.

  2014cited by this paper
• Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

  2014influential reference
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014cited by this paper
• Current perspectives on immunotherapy.

  2014cited by this paper
• Genetic basis for clinical response to CTLA-4 blockade in melanoma.

  2014cited by this paper
• Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

  2014cited by this paper
• Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

  2014influential reference
• Recognition of tumors by the innate immune system and natural killer cells.

  2014cited by this paper
• Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In Vivo

  2014cited by this paper
• RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance

  2014cited by this paper
• A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

  2014cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

  2013cited by this paper
• Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

  2013cited by this paper
• Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

  2013cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013influential reference
• Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.

  2013cited by this paper
• Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.

  2013cited by this paper
• Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization

  2012cited by this paper
• Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012influential reference
• Densely granulated murine NK cells eradicate large solid tumors.

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

  2012influential reference
• Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

  2012influential reference
• Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity

  2012cited by this paper
• Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4

  2011cited by this paper
• MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses

  2011influential reference
• PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice

  2011cited by this paper
• Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

  2010influential reference
• B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance.

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

  2010cited by this paper
• Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

  2010cited by this paper
• CD28 and CTLA‐4 coreceptor expression and signal transduction

  2009cited by this paper
• Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+

  2009cited by this paper
• Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

  2009cited by this paper
• Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

  2009cited by this paper
• Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.

  2009cited by this paper
• Expression of Immunosuppresive B7-H3 Ligand by Hormone-Treated Prostate Cancer Tumors and Metastases

  2009cited by this paper
• Fine tuning the immune response through B7‐H3 and B7‐H4

  2009cited by this paper
• Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

  2009cited by this paper
• LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis1

  2009cited by this paper
• Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

  2009cited by this paper
• The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

  2009cited by this paper
• Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells1

  2009cited by this paper
• Expression of Immunosuppresive B 7-H 3 Ligandby Hormone-Treated Prostate Cancer Tumors andMetastases

  2009cited by this paper
• Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

  2009cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• Tumor Cell and Tumor Vasculature Expression of B7-H3 Predict Survival in Clear Cell Renal Cell Carcinoma

  2008cited by this paper
• CTLA-4 Control over Foxp3+ Regulatory T Cell Function

  2008cited by this paper
• Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

  2008cited by this paper
• Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.

  2007cited by this paper
• Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

  2007cited by this paper
• Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis

  2007cited by this paper
• Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

  2007cited by this paper
• LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.

  2007cited by this paper
• The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells1

  2006cited by this paper
• Response to Comment on “Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade”

  2006cited by this paper
• Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma

  2006cited by this paper
• Identification and characterization of a second CD4-like gene in teleost fish.

  2006cited by this paper
• Reversal of the TCR Stop Signal by CTLA-4

  2006cited by this paper
• Restoring function in exhausted CD8 T cells during chronic viral infection

  2006cited by this paper
• In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses

  2005cited by this paper
• The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

  2005cited by this paper
• Expression of lymphocyte activation gene 3 (LAG‐3) on B cells is induced by T cells

  2005cited by this paper
• Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade

  2005cited by this paper
• Role of LAG-3 in regulatory T cells.

  2004cited by this paper
• Ido expression by dendritic cells: tolerance and tryptophan catabolism

  2004cited by this paper
• CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms

  2004cited by this paper
• Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand

  2004cited by this paper
• B7-H3 Enhances Tumor Immunity In Vivo by Costimulating Rapid Clonal Expansion of Antigen-Specific CD8+ Cytolytic T Cells1

  2004cited by this paper
• Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

  2003cited by this paper
• Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

  2003cited by this paper
• Cooperative B7-1/2 (CD80/CD86) and B7-DC Costimulation of CD4+ T Cells Independent of the PD-1 Receptor

  2003cited by this paper
• Tim-3 inhibits T helper type 1–mediated auto- and alloimmune responses and promotes immunological tolerance

  2003influential reference
• The B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responses

  2003cited by this paper
• Characterization of Mouse and Human B7-H3 Genes1

  2002influential reference
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper

• Immunotherapy-mediated cancer reversion: Possibilities and prospects

  2026cites this paper
• Advanced extracellular vesicle immunotherapy

  2026cites this paper
• Markers of immune activation and immunotherapy responsiveness are increased in 3D Pancreatic cancer organoids when primed with photodynamic- and chemo-therapy.

  2026cites this paper
• Targeting HPK1 for cancer immunotherapy: An update on recent medicinal chemistry advances.

  2026cites this paper
• Bioinformatics and clinical analysis reveal the potential diagnostic and prognostic role of DLD for pan cancer and renal carcinoma

  2026cites this paper
• Detection of PD-1 and CD28 Expression in Lymphocytes by Flow Cytometry.

  2026cites this paper
• Palmitic acid-triggered B7H3 palmitoylation promotes immune escape

  2026cites this paper
• Pain spectrum in immune checkpoint inhibitor-related adverse events: evolution, characteristics and management challenges based on bibliometrics

  2026cites this paper
• Intraperitoneal Paclitaxel-Induced Eosinophil Recruitment as a Potential Mediator of Tumor Response in Peritoneal Metastases from Gastric Cancer.

  2026cites this paper
• Cuproptosis-related gene PROK1 predicts the diagnosis and prognosis of prostate cancer based on multiple machine learning

  2026cites this paper
• PSMD1 inhibition suppresses tumor progression and enhances antitumor immunity by modulating the RTKN/β-catenin/PD-L1 axis in hepatocellular carcinoma

  2026cites this paper
• PD-1 Inhibitors in Orbital and Periocular Squamous Cell Carcinoma: A Review.

  2026cites this paper
• Mechanistic insights into cordycepin-enhanced CTLA-4 blockade efficacy via Eubacterium rectale-mediated immunomodulation in colon cancer.

  2026cites this paper
• Prognostic value of the baseline triglyceride-glucose-body mass index in small cell lung cancer undergoing chemoimmunotherapy: A multicenter retrospective study.

  2026cites this paper
• Discovery of PD-L1 inhibitors featuring novel indole and pyrrolopyridine scaffolds with PD-L1 degradation activity in vivo.

  2026cites this paper
• SERS-enabled immune monitoring: Decoding the tumor microenvironment for precision Cancer immunotherapy.

  2026cites this paper
• PD-L1, CD8 + T-cell density, and CD105 angiogenesis: insights into the tumor microenvironment of hepatocellular carcinoma

  2026cites this paper
• Bibliometric Insights into Aging and Immune Function in Prostate Cancer: Focus on Chronic Inflammation.

  2026cites this paper
• Three Cases of Resection of Alpha-Fetoprotein-Positive High-Grade Fetal Adenocarcinoma of the Lung From a Single Institution.

  2026cites this paper
• Autoimmunity in the era of immune checkpoint inhibitors: the evolving epidemiology of autoimmune diseases and the possible impact of COVID-19.

  2026cites this paper
• Benchmarking cell type deconvolution in spatial transcriptomics and application to cancer immunotherapy

  2026cites this paper
• Production of isotope-labeled nanobody KN035 in Pichia pastoris yields native-like conformation and PD-L1 binding activity comparable to KN035 expressed in mammalian cells

  2026cites this paper
• Recent advances in the nanoparticle-based targeted cancer treatment: A review

  2026cites this paper
• Paraneoplastic neurologic disorders and neurologic complications of immune checkpoint inhibitors.

  2026cites this paper
• Comparative study on predicting postoperative distant metastasis of lung cancer based on machine learning models

  2026cites this paper
• Unmasking the role of tumor microenvironment in the advanced stage of cancer treatment to mitigate risks during chemotherapy.

  2026cites this paper
• Quinoline carboxylic acid derivatives as potent ectonucleotidase inhibitors.

  2026cites this paper
• A comprehensive review of mechanisms underlying resistance to immune checkpoint inhibitors

  2026cites this paper
• Photoactivated Ruthenium-Platinum Complex Enhances Immune Checkpoint Blockade Therapy by Upregulating MHC-I Expression and Inducing Immunogenic Cell Death.

  2026cites this paper
• Precision management of cervical cancer emphasizes immunotherapy combination regimens and translational advances.

  2026cites this paper
• Targeting PTPN13 with 11-amino-acid peptides of C-terminal APC prevents immune evasion of colorectal cancer

  2026cites this paper
• Pharmacological strategies to overcome immune checkpoint inhibitor resistance in non-small cell lung cancer

  2026cites this paper
• Enhanced potency of immune checkpoint inhibitors against poorly immunological solid tumors by immune stimulatory oncolytic adenoviruses-mediated remodeling of the tumor microenvironment

  2025cites this paper
• Anti-Cancer Drugs: Trends and Insights from PubMed Records

  2025influential citation
• Management of immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome: a single institution case series and literature review

  2025cites this paper
• [Regulation of myeloid-derived suppressor cells by glutamate].

  2025cites this paper
• PKM2 modulates chemotherapy sensitivity by regulating autophagy and predicts the prognosis and immunity in pancancer

  2025cites this paper
• PD-1 regulates the anti-tumor immune function of macrophages through JAK2-STAT3 signaling pathway in colorectal cancer tumor microenvironment

  2025cites this paper
• N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1

  2025cites this paper
• Promising New Anti‐TIGIT Agents: Stealthy Allies in Cancer Immunotherapy

  2025cites this paper
• Comprehensive pan-cancer analysis of PPP1R3G reveals its diagnostic, prognostic, and immunotherapeutic implications

  2025cites this paper
• Combination of External Beam Radiation Therapy and Immune Checkpoint Inhibitors in Cancer Treatment: Mechanisms, Limitations, and Clinical Applications

  2025cites this paper
• CD44 on cancer stem cell is a potential immunological and prognostic pan-cancer biomarker

  2025cites this paper
• PD-1/PD-L1 Blockade Based Immunotherapy in Cancer Treatment

  2025cites this paper
• Harnessing Immune Rejuvenation: Advances in Overcoming T Cell Senescence and Exhaustion in Cancer Immunotherapy

  2025cites this paper
• Pembrolizumab in Patients with Advanced Miscellaneous Rare Cancers: Results from a Phase 2 Basket Trial

  2025cites this paper
• Translating Basic Science Discoveries into Clinical Advances: Highlights from the EACR-AACR-IACR 2024 Conference in Celebration of Irish Association for Cancer Research’s 60th Anniversary

  2025cites this paper
• PD-L1/PD-1 checkpoint pathway regulates astrocyte morphogenesis and myelination during brain development

  2025cites this paper
• Advancements in Osteosarcoma Therapy: Overcoming Chemotherapy Resistance and Exploring Novel Pharmacological Strategies

  2025cites this paper
• Tumor-specific CXCR6 positive precursor CD8+ T cells mediate tumor control in metastatic melanoma

  2025cites this paper
• Risk of Autoimmune Skin Diseases Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis Using the FAERS Database

  2025cites this paper
• Memory-promoting function of miR-379-5p attenuates CD8+ T cell exhaustion by targeting immune checkpoints

  2025cites this paper
• Elucidation of the mechanism Underlying the promotion of ferroptosis and enhanced antitumor immunity by citrus polymethoxyflavones in CRC cells

  2025cites this paper
• Checkpoint inhibitor colitis: a gastroenterologists’ perspective

  2025cites this paper
• A novel peptide targeting PD-1: implications for protein-protein interaction studies and immunotherapy.

  2025cites this paper
• PSAT1 impairs ferroptosis and reduces immunotherapy efficacy via GPX4 hydroxylation

  2025influential citation
• Resistance to anti-LAG-3 plus anti-PD-1 therapy in head and neck cancer is mediated by Sox9+ tumor cells interaction with Fpr1+ neutrophils

  2025cites this paper
• Understanding Immune Cell Adaptation to Tumor Hypoxia for Maximized Therapeutic Efficacy of Immunotherapy: Biology and Non-invasive Imaging Application

  2025cites this paper
• A comprehensive pan-cancer analysis of LRFN4: its potential as a prognostic biomarker and therapeutic target for immunotherapy

  2025cites this paper
• Why combine and why neoadjuvant? Tumor immunological perspectives on chemoimmunotherapy in triple-negative breast cancer

  2025cites this paper
• A superior method for antitumor therapy and application: dual-ligand nanomedicines.

  2025cites this paper
• Advances in cancer immunotherapy: historical perspectives, current developments, and future directions

  2025cites this paper
• Preoperative Neoadjuvant Chemotherapy or Immunotherapy in Head and Neck Cancer: A Systematic Review and Meta-Analysis of Surgical Risk and Pathologic Response.

  2025cites this paper
• Effect of Helicobacter Pylori infection on immunotherapy for gastrointestinal cancer: a narrative review.

  2025cites this paper
• Recent advances in oncolytic virus combined immunotherapy in tumor treatment

  2025cites this paper
• PD-L1 expression in prostate cancer and Gleason Grade Group: Is there any relationship? Findings from a multi-institutional cohort.

  2025cites this paper
• The paths toward immunotherapy of esophageal cancer: An overview of clinical trials.

  2025cites this paper
• Utilizing Nanoparticles to Overcome Anti-PD-1/PD-L1 Immunotherapy Resistance in Non-Small Cell Lung cancer: A Potential Strategy

  2025cites this paper
• Gene expression and soluble protein level of PD-1 and its ligands (PD-L1 and PD-L2) in endometrial cancer

  2025cites this paper
• AI-Guided Precision in Antibody Humanization: Structural Modeling to Minimize Immunogenicity and Preserve Efficacy

  2025cites this paper
• MFAP4 is a novel prognostic biomarker in glioma correlating with immunotherapy resistance and ferroptosis

  2025cites this paper
• Ancestry-Specific DNA Damage Repair Gene Mutations and Prostate Cancer

  2025cites this paper
• Bioactive metallic nanoparticles for synergistic cancer immunotherapy

  2025influential citation
• Towards the Prediction of Responses to Cancer Immunotherapy: A Multi-Omics Review

  2025cites this paper
• Water and electrolyte abnormalities in novel pharmacological agents for kidney disease and cancer

  2025cites this paper
• Unveiling 2-Isopropyl-5-methylphenol's Immunomodulatory Potential in Breast Cancer: A Synergistic Computational and Laboratory Investigation.

  2025cites this paper
• CXCL9 and CXCL13 shape endometrial cancer immune‐activated microenvironment via tertiary lymphoid structure formation

  2025cites this paper
• Inflammation in cancer: therapeutic opportunities from new insights

  2025cites this paper
• Automated fast-flow synthesis of the immune checkpoint receptors PD-1 and PD-L1.

  2025cites this paper
• Exploring lung cancer microenvironment: pathways and nanoparticle-based therapies

  2025cites this paper
• Extraction, GC-MS analysis, cytotoxic, anti-inflammatory and anticancer potential of Cannabis sativa female flower; in vitro, in vivo and in silico

  2025cites this paper
• The pan-cancer analysis of LRG1 and its potential role in kidney renal clear cell carcinoma.

  2025cites this paper
• Phytochemical synergies in BK002: advanced molecular docking insights for targeted prostate cancer therapy.

  2025cites this paper
• Whole-Component Antigen Nanovaccines Combined With aTIGIT for Enhanced Innate and Adaptive Anti-tumor Immunity.

  2025cites this paper
• Manganese-coordinated nanoparticles loaded with CHK1 inhibitor dually activate cGAS-STING pathway and enhance efficacy of immune checkpoint therapy.

  2025cites this paper
• Lung Cancer Therapy: The Role of Personalized Medicine

  2025cites this paper
• Eliminating Radioresistance With a Magnetic Ion‐Generator by Simultaneously Augmenting DNA Damage and Diminishing Immunosuppression

  2025cites this paper
• Influence of gut microbial metabolites on tumor immunotherapy: mechanisms and potential natural products

  2025cites this paper
• Tumor immune microenvironment alterations associated with progression in human intraductal papillary mucinous neoplasms

  2025cites this paper
• CDKN2A, a key gene in copper-induced cell death model, influencing melanoma invasion and apoptosis

  2025cites this paper
• Comprehensive analysis of TMEM9 in human tumors

  2025influential citation
• Development of Novel Short Peptide Inhibitor Targeted to Immune Checkpoint PD-1 LBD

  2025cites this paper
• Silencing PTPN2 with nanoparticle-delivered small interfering RNA remodels tumor microenvironment to sensitize immunotherapy in hepatocellular carcinoma

  2025cites this paper
• QRICH1 mediates an intracellular checkpoint for CD8+ T cell activation via the CARD11 signalosome.

  2025cites this paper
• Clinical Characteristics, Prognostic Factors and Therapeutic Strategies in Gastric Cancer Patients With Bone Metastasis: A Retrospective Analysis

  2025cites this paper
• Tumor Heterogeneity and the Immune Response in Non-Small Cell Lung Cancer: Emerging Insights and Implications for Immunotherapy

  2025cites this paper
• MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy

  2025cites this paper
• Microenvironment-based immunotherapy in oral cancer: a comprehensive review

  2025cites this paper
• Immune cell dysfunction: A critical player in development of diabetes complications.

  2025cites this paper
• New approach methodologies to assess wanted and unwanted drugs-induced immunostimulation

  2025influential citation